Pain-Identifying and Commercializing First-in-Class Innovation: Market Analysis and Research

1
Frontier Pharma Pain-Identifying and
Commercializing First-in-Class Innovation
2
Report Description
 
Large and Innovative Pipeline The active pain
pipeline is populated by 796 products across all
stages of development, which exhibit a highly
diverse range of molecular targets. GBI
Researchs analyses identified 122 first-in-class
programs in active development, constituting
13.6 of the pipeline and acting on 65
first-in-class molecular targets, indicating a
high degree of innovation. This is in stark
contrast to the pain therapeutics market, which
has been largely characterized by only
incremental product innovation over the last
decade, as most market segments continue to be
dominated by long-established active
pharmaceutical ingredients and the concomitant
mechanisms of action. Moderate-to-severe pain
continues to be dominated by opioids that are
increasingly being reformulated to offer
abuse-resistance, while mild pain is effectively
treated with Non-Steroidal Anti-Inflammatory
Drugs (NSAID). However, significant unmet needs
remain, as chronic pain and some neuropathic pain
subtypes do not respond well to existing
therapies, which are not adequate to treat
associated hypersensitization and do not align to
the underlying molecular pathophysiological
profile.
3
Report Description
 
Despite being mostly distributed in the early
stages of development, first-in-class innovation
is particularly concentrated on novel molecular
targets that are aligned to the central
sensitization associated with neuropathic pain,
which is arguably the most debilitating and
difficult-to-treat type of chronic pain. This
gives them the potential to transform the future
market by expanding the range of drug
classes. Highly Diversified Range of Innovative
Programs in Early Pipeline and in Granted
Patents Get more about this report at
http//www.bigmarketresearch.com/frontier-pharma-p
ain-identifying-and-commercializing-first-in-class
-innovation-market
4
Report Description
 
Pain is a complex and multifaceted disorder with
a complex interplay between different
pathological processes, and different pain
subtypes exhibit distinct underlying etiologies
and pathophysiologies. While technological
advances and extensive research efforts have
furthered the understanding of these complex
underpinnings, gaps remain. However, these
insights have translated into the expanding pool
of novel therapeutic targets, as reflected by the
highly innovative pipeline. GBI Researchs
proprietary analysis shows that early-stage,
first-in-class programs exhibit a higher level of
diversity with respect to novel therapeutic
targets. The significant diversity in terms of
targets is a reflection of the complex
underpinnings of distinct pain subtypes. Although
the pipeline continues to feature established
therapies, the range of mechanisms of action
employed by novel compounds is extremely diverse,
with the vast majority residing in the
Preclinical stage. This innovation and diversity
is maintained throughout the pipeline from early-
to late-stage development, although the degree of
innovation diminishes from Phase II.
Additionally, although NSAIDs and opioids remain
the cornerstone of pain treatment, GBI Research
analysis indicates a shift towards pain subtypes
that are more difficult to treat.
5
Report Description
 
In addition, GBI Researchs comprehensive and
complementary analysis of granted patents
highlighted a significant number of
first-in-class product technologies, many of
which have not been identified in the pain
product pipelines or even in pipelines across the
industry. The distribution of these products
across the molecular target superfamilies and
families highlighted that they predominantly
align with the proportional distribution observed
across the pain pipeline, with G-protein-coupled
receptors and enzymes inhibitors constituting the
two major categories. However, an array of novel
molecular targets within those groups has been
identified, which do not present in any pipeline
or marketed products across the industry. A
significant degree of innovation has also been
identified in other molecular target
categories. Active Deals Landscape with Numerous
Investment Opportunities The pain deals landscape
has been highly active over the past eight years,
with 261 licensing deals and 112 co-development
deals. However, despite high levels of investment
activity, deals for first-in-class products have
been relatively rare. To Get More Details
Enquire _at_ http//www.bigmarketresearch.com/report-
enquiry/176587
6
Scope

• The report covers and includes
• A brief introduction to pain, including the
  different subtypes of pain, pathophysiology, and
  overview of pharmacotherapy and treatment
  algorithms
• The changing molecular target landscape between
  market and pipeline and particular focal points
  of innovation in the pipeline
• A comprehensive review of the pipeline for
  first-in-class therapies, analyzed on the basis
  of stage of development, molecule type and
  molecular target
• Identification and assessment of first-in-class
  molecular targets with a particular focus on
  early-stage programs of which clinical utility
  has yet to be evaluated, as well as literature
  reviews on novel molecular targets
• Assessment of the licensing and co-development
  deal landscape for pain therapies and
  benchmarking of deals involving first-in-class
  versus non-first-in-class-products
•  

7
Table Of Content
1 Table of Contents 2 Executive Summary 3 The
Case for Innovation 4 Clinical and Commercial
Landscape 5 Assessment of Pipeline Product
Innovation 6 Pain Patent Analysis 7
First-in-Class Target and Pipeline Program
Evaluation 8 Deals and Strategic
Consolidations 9 Appendix
8
FOR MORE DETAILS
Visit us at
http//www.bigmarketresearch.com/frontier-pharma-p
ain-identifying-and-commercializing-first-in-class
-innovation-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone]E-MAIL
sales_at_bigmarketresearch.com